Everolimus, an experimental oral agent that targets the mTOR protein, may represent an effective second-line option for patients with metastatic renal-cell carcinoma whose disease has progressed despite treatment with a tyrosine kinase inhibitor.
Everolimus, an experimental oral agent that targets the mTOR protein, may represent an effective second-line option for patients with metastatic renal-cell carcinoma whose disease has progressed despite treatment with a tyrosine kinase inhibitor.
In a Phase 3 study, everolimus doubled progression-free survival compared with placebo, said Robert J. Motzer, MD, the study's lead investigator. The favorable effect of everolimus was so pronounced that the study was stopped following a planned interim analysis after which 60% of the planned number of events had accrued.
Historically, metastatic renal-cell carcinoma has been one of the most difficult cancers to treat. An effective treatment option after the disease has progressed - despite treatment with targeted agents such as sorafenib and sunitinib - is an unmet clinical need, said Dr. Motzer, attending physician, Memorial Sloane-Kettering Cancer Center, New York City. "It is an unmet clinical need that has now been filled," he said. "Everolimus should be standard of care in this setting."
The study included 410 patients with metastatic renal-cell carcinoma with a clear cell component. All patients had stopped responding to either sorafenib or sunitinib within the previous 6 months. "This was a heavily pretreated group," he said. Patients had received up to three therapies previously.
After 6 months, the median progression-free survival was 4 months in patients assigned to everolimus vs. 1.9 months in those assigned to placebo, a hazard ratio of 0.30 (p < 0.0001). Everolimus was significantly superior to placebo in all three prognostic groups (favorable, intermediate, poor).
The most common adverse events in the everolimus group were stomatitis (incidence of 40% vs. 8% with placebo), anemia (28% vs. 15%), and weakness (28% vs. 20%). The incidence of severe (grade 3 or 4) toxicity was 3% or less for each side effect.
Quality-of-life measures were not significantly different between patients randomized to everolimus or placebo.
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More